AIM ImmunoTech announced the launch of its CEO Corner featuring Thomas K Equels, M.S., J.D., Executive Vice Chairman, CEO & President of AIM ImmunoTech. The CEO Corner platform is intended to provide additional and in-depth perspective to press releases, corporate developments and development pipeline progress. “Keeping our stakeholders well informed is absolutely essential to the future success of AIM ImmunoTech,” states Equels. “CEO Corner is a new way for us to connect directly with both current and potential stockholders. CEO Corner segments will provide expanded perspective on press releases, clinical trials and other corporate advancements as we continue to push forward with our development pipeline. We believe in the future of Ampligen and are dedicated to growing value for all stakeholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AIM:
- AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
- AIM ImmunoTech outlines recent progress across development pipeline
- AIM ImmunoTech Secures $2.5 Million Funding and Debt Terms
- AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
- AIM ImmunoTech announces first subject dosed in Netherlands for Ampligen study
